ITLN1 and atherosclerosis: Indeed, in vivo, omentin slows atherosclerosis: in apolipoprotein E–deficient mice, transgenic overexpression or chronic infusion reduced aortic plaque size, macrophage infiltration, and arterial levels of proinflammatory mediators such as TNF-α, IL-6, and MCP-1 [24,33].